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Abstract
Huntington’s disease (HD) is a neurodegenerative disease caused by mutant huntingtin
protein containing an expanded polyglutamine tract, which may cause abnormal protein–
protein interactions such as increased association with calmodulin (CaM). We previously
demonstrated in HEK293 cells that a peptide containing amino acids 76-121 of CaM
(CaM-peptide) interrupted the interaction between CaM and mutant huntingtin, reduced
mutant huntingtin-induced cytotoxicity and reduced transglutaminase (TG)-modified
mutant huntingtin. We now report that adeno-associated virus (AAV)-mediated expression
of CaM-peptide in differentiated neuroblastoma SH-SY5Y cells, stably expressing an
N-terminal fragment of huntingtin containing 148 glutamine repeats, significantly
decreases the amount of TG-modified huntingtin and attenuates cytotoxicity. Importantly,
the effect of the CaM-peptide shows selectivity, such that total TG activity is not signifi-
cantly altered by expression of CaM-peptide nor is the activity of another CaM-dependent
enzyme, CaM kinase II. In vitro, recombinant exon 1 of huntingtin with 44 glutamines
(htt-exon1-44Q) binds to CaM-agarose; the addition of 10 mM of CaM-peptide significantly
decreases the interaction of htt-exon1-44Q and CaM but not the binding between CaM and
calcineurin, another CaM-binding protein. These data support the hypothesis that CaM
regulates TG-catalyzed modifications of mutant huntingtin and that specific and selective
disruption of the CaM-huntingtin interaction is potentially a new target for therapeutic
intervention in HD.
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INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant neurodegen-
erative disease characterized by chorea and cognitive disturbances
(27). The gene involved in HD, interesting transcript 15 (IT15),
encodes for the protein huntingtin (1). In HD, IT15 has an
expanded CAG trinucleotide repeat in its first exon, resulting in a
mutated form of the huntingtin protein containing an expanded
polyglutamine tract in its N-terminus (34). Medium spiny neurons
in the striatum are selectively vulnerable to neurodegeneration in
HD (47). In HD brains, insoluble deposits that contain amino-
terminal fragments of huntingtin with an expanded glutamine
repeat are found in neurons (12). Huntingtin is a substrate of trans-
glutaminase (TG), and, as the length of the glutamine repeat is
increased, the protein becomes a better substrate (7, 16, 21, 23). It
has been hypothesized that TG modifies huntingtin, thereby aiding
in the stabilization of monomeric huntingtin (48), and the forma-
tion and stabilization of huntingtin containing aggregates (7, 17).
Huntingtin has been shown to interact with many proteins,
including cyclic adenosine monophosphate (cAMP) response-
element binding protein (CREB)-binding protein (CBP) (26),
huntingtin-interacting protein 1 (HIP1), the spliceosome protein
HYPA (18), and calmodulin (CaM) (3). It has also been reported
that mutant huntingtin containing an expanded glutamine repeat
interacts with CaM with a higher affinity than wild-type huntingtin
(3). Interestingly, CaM, a calcium (Ca2+) binding protein that acti-
vates many enzymes, also interacts with TG and increases TG
activity (36). We previously demonstrated that CaM colocalizes
with TG2 and huntingtin protein in intranuclear inclusions in the
HD cortex (49). Furthermore, inhibition of CaM results in
decreased TG-catalyzed modifications of huntingtin in cells
expressing mutant huntingtin and TG2 (49).
TGs (EC2.3.2.13) are a family of enzymes that catalyze a
calcium-dependent acyl-transfer reaction between the g-carboxy
group of a protein-bound glutamine and either the e-amino group
of a protein-bound lysine or a primary amine, resulting in the
formation of an e-(g-glutamyl) lysine bond (15). TG mRNA,
protein levels and activity are all elevated in an HD brain (23, 25,
50). TG-catalyzed e-(g-glutamyl) lysine bonds and TG2 both
colocalize with huntingtin in intranuclear inclusions in HD
brain (48). Treatment of HD-transgenic mice with cystamine, a TG
inhibitor, or knocking out TG2 increases survival (2, 11, 28, 46).
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Similarly, treating cells that express N-terminal mutant huntingtin
and TG2 with cystamine increases cell survival and decreases the
amount of TG-catalyzed modifications of huntingtin (50).
In HD, mutant huntingtin may alter the normal interaction
between CaM and TG. One result could be an increased interaction
between CaM and huntingtin resulting in a subsequent increase in
TG activity. Another possible result could be sequestration of CaM,
thereby inhibiting its biochemical functions such as activation of
nitric oxide synthase (NOS), an enzyme which has been shown to
have decreased activity in an HD mouse model (8). Previously, in
HEK-293 cells transiently expressing N-terminal huntingtin with
an expanded polyglutamine repeat and TG2, we found that a
peptide containing amino acids 76–121 of CaM (CaM-peptide) and
encoded by a fragment of exons 4 and 5 of the CaM gene was able
to decrease the TG-catalyzed modifications of mutant huntingtin,
the cytotoxicity induced by mutant huntingtin and the binding of
mutant huntingtin to CaM (13). The goal of the current study was to
examine the effect of adeno-associated viral (AAV) mediated-
expression of that peptide (CaM-peptide) in differentiated neuro-
blastoma SH-SY5Y cells that stably express an N-terminal (63
amino acids in length) fragment of huntingtin containing 148
glutamines (SH-SY5Y-htt-N63-148Q cells). Previous studies dem-
onstrated that a fragment of CaM from amino acid 78 to 148 was
able to inhibit CaM-induced stimulation of phosphodiesterase and
myosin light chain kinase (MLCK) (29, 30). Therefore, we hypoth-
esized that CaM-peptide would compete with endogenous full-
length CaM for binding to mutant huntingtin, resulting in
inhibition of the endogenous CaM-mutant huntingtin interaction.
We examined the effects that CaM-peptide had on TG-catalyzed
modifications of mutant huntingtin, cytotoxicity associated with
mutant huntingtin, total TG activity and binding of CaM to exon 1
of mutant huntingtin.
MATERIALS AND METHODS
AAV vector construction
A fragment of exons 4 and 5 of the CaM gene, encoding amino
acids 76–121 of CaM [MKDTDSEEEIREAFRVFDKDGNGY
ISAAELRHVMTNLGEKLTDEEV (CaM-peptide)], was cloned
into pEF6. The following website, http://darwin.nmsu.edu/bioinfo/
seqmake/seqmake.php, was used to randomly scramble the amino
acid sequence of CaM-peptide: GDTVEREKDAYNSLEGFDN-
TIHTLRADIGMVEEVAKSKRDEEFLE (scram-CaM-peptide).
This sequence was then analyzed at the National Center for Bio-
technology Information (NCBI) site using the basic local align-
ment search tool (BLAST) network service to identify sequence
similarity with the sequences of other proteins. Once it was deter-
mined that there was no significant similarity with any other
protein sequence, the sequence was synthesized and cloned into
pZERO-2 vector (IDT DNA Technologies, Coralville, IA, USA).
The pEF6 vector encoding CaM-peptide and the pZERO-2 vector
encoding scram-CaM-peptide were used as templates in a multi-
step polymerase chain reaction (PCR) method. CaM-peptide or
scram-CaM-peptide was amplified using primers 1 and 2 or 4 and
5, respectively, containing XhoI and EcoRI restriction sites. The
resultant PCR products were digested and cloned into the XhoI and
EcoRI sites in the pMig vector (generous gift from Dr Vinay
Kumar, University of Chicago), which encodes for an internal ribo-
some entry site (IRES) followed by green fluorescent protein
(GFP). The resultant CaM-peptide-IRES-GFP and scram-CaM-
peptide-IRES-GFP pMig vectors were used as templates to amplify
CaM-peptide-IRES-GFP and scram-CaM-peptide-IRES-GFP
using primers 1 and 3, and 4 and 3, respectively, containing XhoI
and KpnI restriction sites. The resultant PCR products were
digested and cloned into the XhoI and KpnI sites in the pGAN
vector (Gene Transfer Vector Core, University of Iowa, Iowa City,
IA, USA) containing cytomegalovirus (CMV) promoter and
bovine growth hormone polyadenylation signal. The resultant
CMV-CaM-peptide-IRES-GFP and CMV-scram-CaM-peptide-
IRES-GFP pGAN vectors were then subcloned into NotI restriction
sites in the pFBGR vector (Gene Transfer Vector Core, University
of Iowa, Iowa City, IA, USA) containingAAV elements. Constructs
were verified by restriction digests and sequencing. The resultant
vectors as well as an empty pFBGR vector, which encodes for GFP
only, were then used for production of the AAV 2 expressing either
CaM-peptide and GFP (AAV-CaM-peptide + GFP), scram-CaM-
peptide and GFP (AAV-scram-CaM-peptide + GFP), or only GFP
(AAV-GFP) (Gene Transfer Vector Core, University of Iowa, Iowa
City, IA, USA).
PCR primers used for generating vectors:
● Primer 1: ACT CGA CTC GAG ATC ATG AAG GAC ACA
GAC AGT GAG;
● Primer 2: ACT CGA GAA TTC CTA CAC CTC CTC ATC GGT
CAG CTT C;
● Primer 3: ACT CGA GGT ACC TTA CTT GTA CAG CTC GTC
CAT GCC;
● Primer 4: ACT CGA CTC GAG ATC ATG GGC GAT ACC GTG
GAA CG;
● Primer 5: ACT CGA GAA TTC CTA TTC CAG AAA TTC TTC
ATC ACG.
Cell culture
Human SH-SY5Y cells were grown at 37°C in RPMI 1640
medium (Invitrogen, Carlsbad, CA, USA) containing 4 mM
glutamine, 5% fetal bovine serum (FBS), 10% horse serum,
100 units/mL penicillin and 100 mg/mL streptomycin in the pres-
ence of 5% CO2. Cells were grown to 80%–90% confluency and
transfected with a 63-amino acid N-terminal huntingtin fragment
containing 148 polyglutamine repeats (htt-N63-148Q) using Lipo-
fectamine Plus (Invitrogen, Carlsbald, CA, USA). Cells stably
expressing htt-N63-148Q were selected based on their resistance to
blasticidin. Cells were treated with 10 mM retinoic acid (Sigma, St.
Louis, MO, USA) for 4 days to induce differentiation and upregu-
late TG expression (44), and then were infected with either AAV-
CaM-peptide + GFP, AAV-scram-CaM-peptide + GFP or AAV-
GFP at a multiplicity of infection (MOI) of 50.
Fluorescence microscopy
Cells were infected with either AAV-CaM-peptide + GFP, AAV-
scram-CaM-peptide + GFP or AAV-GFP, and plated onto collagen-
coated chamber slides. Forty-eight hours post-infection, cells
were washed in phosphate buffered saline (PBS) and fixed in
4% paraformaldehyde for 20 minutes at room temperature, then
washed again in PBS. Coverslips were mounted with media
containing 4′,6-diamidino-2-phenylindole (DAPI). Cells were
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examined using an Olympus (Tokyo, Japan) fluorescent inverted
research microscope configured with Image-Pro Plus 4.5 software
(VayTek, Fairfield, IA, USA). Monochrome images were captured
using Retiga EX 1350 camera and Volume Scan 3.1 software
(VayTek, Fairfield, IA, USA) and were pseudocolored and merged
using Image-Pro Plus 4.5 software.
Flow cytometry
Forty-eight hours post-viral infection, cells were harvested and
centrifuged at 1500 g for 5 minutes. Cell pellets were washed twice
in PBS with 1% bovine serum albumin (BSA). The cell pellets
were then resuspended in 300 mL PBS with 1% BSA and were
analyzed on a GFP channel using BD FACSTM caliber flow cytomer
(BD Biosciences). Data were analyzed on the summit software
suite (Dako Cytomation, Carpenteria, CA, USA).
Immunoprecipitation
Forty-eight hours post-viral infection, cells were harvested and
resuspended in lysis buffer containing 50 mM Tris–HCl, pH 8.8,
100 mM NaCl, 5 mM MgCl2, 0.5% NP-40, 1 mM ethylenedi-
aminetetraacetic acid (EDTA) (19) and 1:1000 protease inhibitor
mixture (Sigma, St. Louis, MO, USA). Insoluble fractions were
prepared by centrifuging the cell lysates at 12 000 g for 5 minutes,
removing the supernatant, resuspending the pellet in 95% formic
acid and incubating at 37°C for 40 minutes. The formic acid was
then removed under vacuum (19). The pellets were then resus-
pended in 10 mM Tris–HCl, pH 7.5, 0.14 M NaCl and 0.1% Tween
20, for further analysis. Immunopurification of proteins containing
TG-catalyzed e-(g-glutamyl) lysine bonds was performed using
81D4 Mab pre-bound to sepharose beads using a protocol devel-
oped by CovalAb (Lyon, France) and as previously described (31).
The eluted immunopurified proteins were stored at -80°C until
immunoblot analysis.
Immunoblots
Proteins were separated on 12% sodium dodecyl sulfate (SDS)-
polyacrylamide gels then electrophoretically transferred to nitro-
cellulose membranes. Membranes were blocked in 5% nonfat dried
milk in Tris-buffered saline (TBS) with 0.1% Tween 20. After
overnight incubation in primary antibody, membranes were incu-
bated in secondary antibody conjugated to horseradish peroxidase
(Jackson ImmunoResearch, West Grove, PA, USA). Signal was
detected using enhanced chemiluminescence (ECL) Western blot-
ting detection reagents (Amersham Biosciences, Piscataway, NJ,
USA). Immunoblots were quantified by calculating the sum of the
densities of all of the pixels within each protein band as the inte-
grated optical density (IOD) using Scion Image for Windows
(Scion, Frederick, MD, USA). Film background IOD was mea-
sured and subtracted from the IOD of each band. Measurements
were done in triplicate and the means were calculated.
Antibodies
The mouse anti-myc monoclonal antibody directed against the
amino acid sequence EQKLISEEDL was used at a 1:1000 for
immunoblots (Invitrogen, Carlsbad, CA, USA) in order to detect
N-terminal huntingtin. The mouse anti-actin antibody was used at
1:10 000 for immunoblots (MP Biomedicals, Solon, OH, USA) in
order to detect actin.
Cytotoxicity assay
Forty-eight hours post-viral infection, lactate dehydrogenase
(LDH) assays were performed on the cells using the CytoTox 96®
Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI,
USA). Briefly, half the media from the cells was removed and
placed in the wells of a 96-well plate. Then, the cells were frozen in
the remaining media at -80°C followed by thawing in order to lyse
the cells. The cells and media were briefly centrifuged and the
media was removed and placed in the remaining wells of the
96-well plate. Substrate solution was added to all samples and
incubated at room temperature in the dark for 30 minutes. Stop
solution was added, and the absorbance was recorded at 490 nm.
Percent cytotoxicity was determined by the ratio of LDH activity in
the media before lysing the cells to the LDH activity in the media
after the cells were lysed.
Ex vivo TG assay
In this ex vivo assay, TG activity is measured in cell lysates. 96-well
Immulon 4 HBX plate (Dynatech, Franklin, MA, USA) was coated
with N-N dimethylcasein (Sigma, St. Louis, MO, USA) in sodium
bicarbonate overnight at 4°C. Then, the plates were washed with
PBS and blocked with 2% milk in PBS for 1 h at 37°C, followed by
three washes with PBS. Forty-eight hours post-viral infection, cells
were harvested and lysed in 0.1 M Tris–HCl, pH 8.3, 1 mM EDTA,
1 mM phenylmethanesulfonyl fluoride (PMSF) and protease
inhibitor cocktail. Cell lysates (25 mg of protein/sample) were
diluted in 0.1 M Tris–HCl pH 8.5, 0.15 M NaCl, 5 mM dithiothrei-
tol (DTT), 0.5 mM biotin labeled amine and 5 mM CaCl2. The
mixture was then added to the wells in triplicate and incubated for
1 h at 37°C. The plate was washed with TBS and 0.001% Tween
followed by incubation with streptavidin conjugated to HRP
(Jackson ImmunoResearch, West Grove, PA, USA) for 1 h at room
temperature. After a final wash, 1 ¥ tetramethylbenzidine (TMB)
substrate solution (eBioscience, SanDiego, CA, USA) was added
and color was allowed to develop for 5–10 minutes. Then, the
reaction was stopped with 3 N sulfuric acid and the absorbance was
read at 450 nm.
In situ TG assay
In this in situ assay, TG activity is measured in intact cells via
incorporation of a polyamine and the presence of the TG-catalyzed
bond. Forty-two hours post-viral infection, cells were treated
with 2 mM 5-(biotinamido)pentylamine, a biotinylated polyamine
(Pierce, Rockford, IL, USA), and 6 h post-polyamine treatment,
cells were harvested and lysed in 0.1 M Tris–HCl pH 8.3, 1 mM
EDTA, 1 mM PMSF and protease inhibitor cocktail. 96-well
Immulon 4 HBX plates were coated with anti-e-(g-glutamyl) lysine
(81D4) antibody (CovalAb, Lyon, France) in 0.1 M Na2HPO4·7
H2O pH 9 overnight at 4°C. Then the plates were washed with PBS
and blocked with 2% milk in PBS for 1 h at room temperature,
followed by 3 washes with PBS with 0.0375% Tween. Cell lysates
(50 mg of protein/sample/well) were added to the wells in
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triplicates and incubated for 1 h at 37°C. The plate was washed
with PBS and 0.0375% Tween, followed by incubation with
streptavidin conjugated to HRP (Jackson ImmunoResearch, West
Grove, PA, USA) for 1 h at room temperature. After final washes, a
1 ¥ TMB substrate solution was added and color was allowed to
develop for 5–10 minutes. The reaction was stopped with 3 N sul-
furic acid and the absorbance was read at 450 nm.
CaM kinase II activity assay
CaM kinase II enzyme activity was analyzed using the Signa-
TECT® Calcium/Calmodulin-Dependent Protein Kinase Assay
System (ProMEGA, Madison, WI, USA), according to the manu-
facturer’s protocol as well as without the addition of exogenous
CaM. Briefly, SH-SY5Y cells were transfected with vector (V),
htt-N63-148Q (H) + V, CaM-peptide + V, or H + CaM-peptide
using Lipofectamine Plus (Invitrogen, Carlsbald, CA, USA). Forty-
eight hours post-transfection cells were lysed in CaM kinase
extraction buffer [20 mM Tris–HCl, pH 8.0, 2 mM EDTA, 2 mM
ethylene glycol tetraacetic acid (EGTA), 2 mM DTT, 1 mM PMSF
and 1:1000 protease inhibitor cocktail (Sigma, St Louis, MO,
USA)]. Cell lysates were mixed with (g-32P) adenosine tri-
phosphate (ATP) (at 3000 Ci/mmol, 10 mCi/mL), activation buffer
containing 5 mM CaCl2 and 5 mM calmodulin or control buffer
containing 5 mM EGTA, with and without biotinylated CaM
kinase II substrate. After incubation at 30°C for 2 minutes, the
reaction was terminated by adding 7.5 M guanidine hydrochloride
and spotted to a streptavidin-impregnated membrane. Membranes
were washed and retained radioactivity was quantitated by liquid
scintillation counting (Beckman, Fullerton, CA, USA). Radioac-
tive counts were converted to endogenous CaM kinase II activity in
the sample by the following formula:
Enzyme activity in pmol min g  of protein
cpmreaction with
μ( ) =
 calcium calmodulin
reaction without calcium calmodulincpm
−(
) × ( )
× ( ) ×
37.5
20 amount of protein in reaction
specific act
gμ
ivity of - P ATPγ 32[ ]( )
Expression and purification of recombinant
mutant huntingtin protein
Escherichia coli expressing a modified pMAL vector (New
England Biolabs, Ipswich, MA, USA) encoding exon 1 of hunting-
tin with 44 glutamine residues (kindly provided by Dr Christopher
Ross, The Johns Hopkins University School of Medicine, Balti-
more, MD) were grown to an OD600 of 0.6–0.8, induced by adding
0.3 mM isopropyl-b-D-thiogalactopyranoside followed by shaking
for 2 h at 28°C, and then centrifuged for 15min at 5000 g. The cell
pellets were then resuspended in lysis buffer [PBS pH 7.4, supple-
mented with 10 mM methionine, 2 mM EDTA, 5 mM dithiothrei-
tol, 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, and protease
inhibitor mixture (Sigma, St. Louis, MO)] and samples were frozen
in a dry ice-ethanol mixture. Samples were then thawed on ice
followed by sonication and then centrifuged at 20 000 g for 15
minutes. To purify maltose binding protein (MBP) fusion proteins,
the supernatant was applied to an amylose resin (New England
Biolabs, Ipswich, MA, USA) packed column (2.5 ¥ 10 cm) that
had first been washed with eight column volumes of PBS pH 7.4.
After addition of the lysate supernatant, the column was then
washed with 12 column volumes of PBS pH 7.4, followed by
elution of the fusion protein with two column volumes of PBS with
10 mM maltose. The fusion protein was further purified by incubat-
ing with Ni-NTA agarose (Qiagen, Valencia, CA, USA) in PBS
supplemented with 10 mM imidazole with rocking for 2 h at 4°C.
The resin was then washed three times with PBS supplemented
with 20 mM imidazole, and fusion protein was eluted with six resin
volumes of PBS supplemented with 250 mM imidazole. Purified
fusion protein was analyzed by SDS-polyacrylamide gel electro-
phoresis (PAGE) and visualized by Coomassie staining.
In vitro mutant huntingtin-CaM binding
Binding of purified mutant huntingtin to calmodulin was studied
using CaM-agarose (Sigma, St. Louis, MO, USA). Purified mutant
huntingtin protein (8.4 mg/mL) or purified calcineurin protein
(1.4 mg/mL, positive control; Sigma, St. Louis, MO, USA), with or
without varying concentrations of purified CaM-overlap peptide
(Biopeptide Co. Inc., San Diego, CA, USA) and/or varying con-
centrations of N-(6-Aminohexyl)-1-naphthalenesulfonamide
hydrochloride (W-5), a calmodulin antagonist (Tocris, Ellisville,
MO, USA), were mixed with 45 mg/mL CaM-agarose in 10 mM
Tris–HCl (pH 8) containing 1 mM CaCl2 and 150 mM NaCl, and
then incubated overnight at 4°C. After washing three times with
20 mM Hepes pH 7.4, 150 mM NaCl, 5 mM sodium pyrophos-
phate, 10% glycerol, 1% Triton X-100, 1 mM CaCl2 and protease
inhibitor mixture (Sigma, St. Louis, MO, USA), and once with
10 mM Hepes pH 7.4, the agarose-bound proteins were eluted by
incubation at 100°C for 10 minutes in Laemmli sample loading
buffer. The fractions obtained were analyzed by SDS-gel electro-
phoresis followed by immunoblotting.
Statistics
All statistical analyses were performed using GB Stat software
(Dynamic Microsystems, Inc., Silver Spring, MD, USA). Data are
expressed as means  standard error of the mean (SEM). Analysis
of Variance (ANOVA) or a two-tailed Student’s t-test was used to
analyze the data. Post-hoc comparisons were conducted using a
Newman–Keuls test.
RESULTS
AAV-mediated expression of CaM-peptide in
human neuroblastoma SH-SY5Y cells that stably
express N-terminus of mutant huntingtin
We developed three different AAVs: an AAV which mediates
expression of a peptide consisting of amino acids 76–121 of CaM,
CaM-peptide, along with GFP (AAV-CaM-peptide + GFP), an
AAV which mediates expression of a scrambled version of CaM-
peptide along with GFP (AAV-scram-CaM-peptide + GFP) and an
AAV which mediates expression of only GFP (AAV-GFP). In order
to determine an appropriate MOI for the AAV, SH-SY5Y cells were
transduced with varying MOIs (0, 0.01, 0.1, 1, 5, 10, 50, 75, 100) of
AAV-GFP. Forty-eight hours post-infection cells were assessed for
AAV-mediated GFP expression using flow cytometry (Figure 1A).
An MOI of 50 resulted in the largest percentage of GFP-positive
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SH-SY5Y cells with the lowest level of cell death. To determine if
an MOI of 50 resulted in similar intracellular distribution and
expression of GFP in differentiated SH-SY5Y cells for all three
AAV developed, we performed fluorescence microscopy. An MOI
of 50 for each of the viruses showed similar AAV-mediated GFP
expression in differentiated SH-SY5Y cells (Figure 1B).
Next, we developed human neuroblastoma SH-SY5Y cell lines
that stably express N-terminal mutant huntingtin. Expression
levels of each cell line were estimated by Western blot analysis,
and cell lines that showed moderate and similar expression were
selected (Figure 2A). To further investigate the viral infection
procedure, we used flow cytometry to quantitatively determine
if an MOI of 50 would result in similar levels of infection for
all three AAVs (AAV-CaM-peptide + GFP, AAV-scram-CaM-
peptide + GFP or AAV-GFP) in differentiated SH-SY5Y cells not
expressing mutant huntingtin (non-htt-SHSY5Y cells) and in dif-
ferentiated SH-SY5Y cells that stably express mutant huntingtin
(SHSY5Y-htt-N63-148Q cells). Non-htt-SHSY5Y and SHSY5Y-
htt-N63-148Q cells were treated with 10 mM retinoic acid for 4
days to induce differentiation. Then, cells were infected with
either AAV-CaM-peptide + GFP, AAV-scram-CaM-peptide + GFP
or AAV-GFP (MOI = 50). Forty-eight hours post-infection, cells
were assessed for GFP expression by flow cytometry. All three
viruses infected differentiated non-htt-SHSY5Y and SHSY5Y-
htt-N63-148Q cells with similar efficiencies (Figure 2B).
However, these values were lower than previously measured for
this MOI, perhaps caused by conditions associated with neuronal
differentiation.
AAV-mediated expression of CaM-peptide
decreases TG-catalyzed modifications of mutant
huntingtin in SH-SY5Y-htt-N63-148Q cells
With the cell and viral system now defined, we determined the
effect of viral-mediated expression of CaM-peptide in differenti-
ated SHSY5Y-htt-N63-148Q cells on TG-catalyzed modifications
of N-terminal mutant huntingtin. Cells were differentiated, infected
with either AAV-CaM-peptide + GFP, AAV-scram-CaM-peptide +
GFP or AAV-GFP (MOI = 50), and forty-eight hours post-infection
cells were assayed for TG-modified N-terminal mutant huntingtin.
SHSY5Y-htt-N63-148Q cells expressing CaM-peptide had a sig-
nificantly lower amount of TG-modified N-terminal huntingtin
compared with cells expressing scram-CaM-peptide or only GFP
(Figure 3).
AAV-mediated expression of CaM-peptide
decreases mutant huntingtin associated
cytotoxicity in neuroblastoma cell lines that
express N-terminal mutant huntingtin
Differentiated non-htt-SHSY5Y or SHSY5Y-htt-N63-148Q cells
were infected with either AAV-CaM-peptide + GFP, AAV-scram-
CaM-peptide + GFP or AAV-GFP (MOI = 50), and forty-eight
hours post-infection levels of cytotoxicity were measured.
SHSY5Y-htt-N63-148Q cells expressing CaM-peptide had
approximately half the level of cytotoxicity compared with
SHSY5Y-htt-N63-148Q cells expressing scram-CaM-peptide or
only GFP. Furthermore, there was no significant difference in
the level of cytotoxicity between SHSY5Y-htt-N63-148Q cells
expressing CaM-peptide and non-htt-SHSY5Y cells (Figure 4).
Differentiated SHSY5Y cells transiently transfected with either
htt-N63-18Q or htt-N63-148Q were infected with either AAV-
CaM-peptide + GFP or AAV-scram-CaM-peptide + GFP, or were
uninfected (MOI = 50), and 96 h post-infection levels of cytotox-
icity were measured using the LDH assay. In cells transiently
transfected with htt-N63-18Q, we found that infection with AAV-
CaM-peptide had no effect on cytotoxicity (38.1  1.1; mean
percent cytotoxicity  SEM) compared with cells infected with
AAV-scram-CaM-peptide (35.4  2.4) or uninfected cells
(38.0  1.3). However, in these transiently transfected cells, there
was also no increase in cytotoxicity in cells transfected with htt-
N63-148Q (34.6  2.3) compared with cells transfected with htt-
N63-18Q (38.0  1.3). The lack of toxicity of the htt-N63-148Q
was perhaps caused by the lower levels of expression of the htt-
N63 constructs in transiently transfected cells compared with
stable transfections.
Effect of AAV-mediated expression of
CaM-peptide on total TG activity in
neuroblastoma cell lines that stably express
N-terminal mutant huntingtin
Next, we examined the effect of expression of the CaM-peptide on
total TG activity in differentiated non-htt-SHSY5Y and SHSY5Y-
htt-N63-148Q cells. Cells were infected with either AAV-CaM-
peptide + GFP, AAV-scram-CaM-peptide + GFP or AAV-GFP
(MOI = 50), and harvested forty-eight hours post-infection. TG
activity was measured ex vivo based on the incorporation of
5-(biotinamido)pentylamine into the N,N′-dimethylcasein sub-
strate coated onto micro-plates. There were no significant dif-
ferences in total TG activity between the different infections
[AAV-CaM-peptide + GFP, AAV-scram-CaM-peptide + GFP or
AAV-GFP (control)] in either non-htt-SHSY5Y cells or SHSY5Y-
htt-N63-148Q cells (Figure 5A). There were small but insignificant
increases in total TG activity in SHSY5Y-htt-N63-148Q cells
expressing scram-CaM-peptide or only GFP, compared with non-
htt-SHSY5Y cells expressing either GFP only, scram-CaM-peptide
or CaM-peptide (Figure 5A). To determine whether cell lysis had
an effect on enzyme activity, we measured total TG activity in situ.
Non-htt-SHSY5Y and SHSY5Y-htt-N63-148Q cells were infected
with one of the various AAV, and 42 h post-infection, were treated
with 5-(biotinamido)pentylamine. Six hours later, cells were har-
vested and the cell lysates were applied to micro-plates coated with
anti-e-(g-glutamyl) lysine (81D4) antibody in order to capture
Figure 1. AAV-mediated expression of GFP in SH-SY5Y cells. A.
SH-SY5Y cells were infected with varying MOIs (0, 0.01, 0.1, 1, 5, 10, 50,
75, 100) of AAV-GFP. Forty-eight hours post-infection cells were
assessed for percent AAV-mediated GFP expression by flow cytometry.
B. Differentiated SH-SY5Y were infected with either AAV-CaM-peptide,
AAV-scram-CaM-peptide or AAV-GFP (MOI = 50). Forty-eight hours post-
infection cells were examined with fluorescence microscopy to examine
AAV-mediated GFP expression. Abbreviations: AAV = adeno-associated
virus; CaM = calmodulin; FITC = fluorescein isothiocyanate; GFP =
green fluorescent protein; MOI = multiplicity of infection.

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proteins that were modified by TG in situ. TG-catalyzed incorpora-
tion of 5-(biotinamido)pentylamine into cellular proteins was then
determined by incubation with streptavidin-HRP. Similar to the ex
vivo assay, there was no significant difference in total TG activity
between the various infections [CaM-peptide, scram-CaM-peptide
or GFP (control)] in SHSY5Y-htt-N63-148Q cells (Figure 5B).
Similarly, there also was no difference in total TG activity in the
various infections in non-htt-SHSY5Y cells. However, there was a
Figure 2. AAV infection (MOI 50) of differentiated neuroblastoma
SH-SY5Y cells stably expressing N-terminal mutant huntingtin. A.
Western blot analysis of human neuroblastoma SH-SY5Y cells stably
expressing N-terminal mutant huntingtin. SH-SY5Y cells were trans-
fected with N-terminal mutant huntingtin with an expanded poly-
glutamine repeat (SHSY5Y-htt-N63-148Q cells) and were selected based
on their resistance to blasticidin. Blot was probed for N-terminal mutant
huntingtin (upper) and actin (lower). B. Non-htt-SHSY5Y cells and
SHSY5Y-htt-N63-148Q cells were treated with 10 mM retinoic acid for 4
days and then infected with either AAV-CaM-peptide, AAV-scram-CaM-
peptide, or AAV-GFP (MOI = 50). Forty-eight hours post-infection cells
were assessed for percent AAV-mediated GFP expression by flow
cytometry. Abbreviations: AAV = adeno-associated virus; CaM =
calmodulin; GFP = green fluorescent protein; non-htt-148Q = SH-SY5Y
cells not expressing mutant huntingtin.
Figure 3. The level of TG-modified N-terminal mutant huntingtin in the
SHSY5Y-htt-N63-148Q cells expressing CaM-peptide was significantly
lower than in SHSY5Y-htt-N63-148Q cells expressing GFP (control) or
scram-CaM-peptide. A. Quantification of immunoblot depicted graphi-
cally. B. Representative immunoblot of protein immunoprecipitated
using the 81D4 antibody (for TG-catalyzed bonds) conjugated to
sepharose. Blot was probed for N-terminal mutant huntingtin. Data
shown are the mean IOD  SEM (n = 3). One-way analysis of variance
(F(2,8) = 7.032, P < 0.0267) and Newman-Keuls comparison. * indicates
P < 0.05 compared with SHSY5Y-htt-N63-148Q infected with AAV-GFP
and + indicates P < 0.05 compared with SHSY5Y-htt-N63-148Q infected
with AAV-scram-CaM-peptide. Abbreviations: AAV = adeno-associated
virus; CaM = calmodulin; GFP = green fluorescent protein; IOD =
integrated optical density; non-htt-148Q = SH-SY5Y cells not expressing
mutant huntingtin; TG = transglutaminase.
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significant decrease in total TG activity in non-htt-SHSY5Y cells
compared with SHSY5Y-htt-N63-148Q cells expressing scram-
CaM-peptide or only GFP. Total TG activity in non-htt-SHSY5Y
cells was not significantly different from total TG activity
in SHSY5Y-htt-N63-148Q cells expressing CaM-peptide
(Figure 5B).
CaM-peptide does not significantly affect CaM
kinase II activity
To determine if expression of CaM-peptide has effects on the
activity of other CaM-dependent enzymes, we examined whether
expression of CaM-peptide affects CaM-dependent protein kinase
II (CaM kinase II) activity. SH-SY5Y cells were transfected with
vector, htt-N63-148Q, CaM-peptide or a combination of htt-N63-
148Q and CaM-peptide. We found no significant differences in
CaM kinase II activity among the various transfections (Figure 6).
Interestingly, expression of CaM-peptide alone resulted in a small
but insignificant increase in CaM kinase II activity compared with
all other transfections. We also examined the activity of CaM
kinase II without the addition of exogenous CaM (addition of exog-
enous CaM is recommended, as described in the manufacturer’s
protocol). There was no significant effect of CaM-peptide under
these assay conditions either (Figure 6).
CaM-peptide inhibits binding of N-terminal
mutant huntingtin with an expanded
polyglutamine repeat and CaM
Thus far, all the experiments performed to examine the effects of
CaM-peptide were done in cells where other endogenous proteins
could play a role in mediating the action of CaM-peptide. There-
fore, an in vitro assay was used to determine if CaM-peptide could
directly interfere with the interaction of N-terminal mutant hun-
tingtin and CaM. CaM-agarose was used to immunoprecipitate
Figure 4. The level of cytotoxicity in SHSY5Y-htt-N63-148Q cells
expressing CaM-peptide was significantly lower than in SHSY5Y-htt-N63-
148Q cells expressing GFP (control) or scram-CaM-peptide. Lactate dehy-
drogenase levels were measured and used as an index of cytotoxicity.
Data shown are the mean  standard error of the mean (n = 3). Two-way
ANOVA [Factor: Virus (F(2,12) = 7.514, P = 0.0077)]; Factor: Huntingtin
(F(1,12) = 19.73, P < 0.0008.); Virus ¥ Huntingtin (F(2,12) = 3.552, P =
0.0614)) and Newman-Keuls comparison. * indicates P < 0.05 and **
indicates P < 0.01 compared with SHSY5Y-htt-N63-148Q cells infected
with AAV-GFP. # indicates P < 0.05 and ## indicates P < 0.01 compared
with SHSY5Y-htt-N63-148Q cells infected with AAV-scram-CaM-peptide.
Abbreviations: AAV = adeno-associated virus; CaM = calmodulin; GFP =
green fluorescent protein; TG = transglutaminase.
Figure 5. There were no significant differences in total ex vivo or in situ
TG activity in non-htt-SHSY5Y cells or SHSY5Y-htt-N63-148Q cells
expressing CaM-peptide, scram-CaM-peptide or GFP. A. There were no
significant differences in total ex vivo TG activity in non-htt-SHSY5Y cells
expressing either CaM-peptide, scram-CaM-peptide or GFP (control).
There was a small but insignificant increase in total ex vivo TG activity in
SHSY5Y-htt-N63-148Q cells expressing scram-CaM-peptide or GFP
compared with non-htt-SHSY5Y cells and SHSY5Y-htt-N63-148Q cells
expressing CaM-peptide. B. Similarly there were no significant differ-
ences in total in situ TG activity in non-htt-SHSY5Y cells expressing
CaM-peptide, scram-CaM-peptide or GFP. However, total in situ TG activ-
ity was significantly less in non-htt-SHSY5Y cells compared with
SHSY5Y-N63-htt-148Q cells expressing scram-CaM-peptide or GFP. But,
total in situ TG activity in non-htt-SH-SY5Y cells was not significantly
different from total TG activity in SH-SY5Y-htt-N63-148Q cells expressing
the CaM-peptide. A. Data shown are the mean  standard error of the
mean (SEM; n = 3). Two-way analysis of variance (ANOVA) [Factor:
Virus (F(2,12) = 2.613, P = 0.1143)]; Factor: Huntingtin (F(1,12) = 24.16,
P < 0.0004); Virus ¥ Huntingtin [F(2,12) = 1.016, P = 0.3911] and
Newman–Keuls comparison. B. Data shown are the mean  SEM
(n = 3). Two-way ANOVA [Factor: Virus (F(2,12) = 1.722, p = 0.22)]; Factor:
Huntingtin (F(1,12) = 6.139, P < 0.0291); Virus ¥ Huntingtin (F(2,12) =
0.2775, P = 0.7624) and Newman–Keuls comparison. * indicates
P < 0.05 compared with SHSY5Y-htt-N63-148Q cells infected with AAV-
GFP. # indicates P < 0.05 compared with SHSY5Y-htt-N63-148Q cells
infected with AAV-scram-CaM-peptide. Abbreviations: AAV = adeno-
associated virus; CaM = calmodulin; GFP = green fluorescent protein;
TG = transglutaminase.
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recombinant purified huntingtin exon 1 with an expanded poly-
glutamine repeat (htt-exon1-44Q) in the absence and presence of
varying concentrations of CaM-peptide. The amount of CaM-
bound htt-exon1-44Q was significantly lower when 10 mM of
CaM-peptide was present than when CaM-peptide was absent
(Figure 7A,B). To determine if CaM-peptide would non-
specifically inhibit the interaction of CaM with any CaM-binding
protein, we incubated calcineurin with CaM-agarose in the absence
and presence of 10 mM of CaM-peptide. The presence of 10 mM of
CaM-peptide did not affect the binding of CaM with calcineurin
(Figure 7C,D). Next, to investigate the potential site of interaction
of CaM-peptide, the CaM antagonist, W-5, was used along with
CaM-peptide. W-5 alone did not affect the amount of CaM-bound
htt-exon1-44Q, but once again the amount of CaM-bound htt-
exon1-44Q was significantly lower when 10 mM of CaM-peptide
was present. However, the amount of CaM-bound htt-exon1-44Q
was significantly increased when 664 mM W-5 is present along
with 10 mM of CaM-peptide (Figure 8).
DISCUSSION
The disease-causing mutation in HD is an expanded polyglutamine
repeat in huntingtin protein. This mutant form of huntingtin
becomes a better substrate for TG (6, 16, 21, 23, 50) and has
Figure 6. Expression of CaM-peptide in N-terminal mutant huntingtin
expressing cells does not significantly affect CaM kinase II activity or
expression. A. SH-SY5Y cells were transfected with vector (V), htt-
N63-148Q (H) + V, CaM-peptide + V, or H + CaM-peptide. Cells were
harvested 48 h post-transfection and CaM kinase II activity was evalu-
ated by the SigmaTECT CaM kinase II Assay System as per the manu-
facturer’s directions. Data shown are the mean  standard error of
the mean (SEM; n = 3). One-way analysis of variance (ANOVA)
(F(3,8) = 2.669, P = 0.1187) and Newman-Keuls Multiple comparison
indicate no significant differences among groups. B. The CaM kinase II
assay was also performed in the absence of exogenous calmodulin.
Data shown are the mean  SEM. Two-way ANOVA indicates a signifi-
cant main effect of EGTA (F(1,16) = 143.37, P < 0.0001). However, there
was no significant main effect of transfection on CaM kinase II activity
(F(3,16) = 0.86, P = 0.48). The interaction between EGTA and transfection
was also not significant (F(3,16) = 1.89, P = 0.17). Newman-Keuls mul-
tiple comparison test indicates no significant differences in CaM
kinase II activity among the various transfections in either the pres-
ence or absence of EGTA. C. Top, protein expression of CaM kinase II
remained at the same level after transfections of either htt-N-148Q (H),
CaM-peptide or the combination of those two constructs. Middle, myc
antibody was used to confirm the expression of htt-N-148Q. Bottom,
equal loading was verified by reprobing the same membrane with
an actin antibody. Abbreviations: CaM = calmodulin; EGTA = ethylene
glycol tetraacetic acid; H = htt-N63-148Q.
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increased interaction with CaM (3, 49). Interestingly, TG is posi-
tively regulated by CaM (5, 36, 49). Therefore, we hypothesized
that the interactions between mutant huntingtin, CaM and TG may
be deleterious. Previously, we found in HEK-293 cells transiently
expressing N-terminal mutant huntingtin, TG2 and a peptide
containing amino acids 76–121 of CaM CaM-peptide that
TG-catalyzed modifications of mutant huntingtin were reduced,
cytotoxicity associated with mutant huntingtin protein was reduced
and carbacol-stimulated calcium release was normalized (13). In
order to test the effects of CaM-peptide in an HD transgenic mouse
model, we created an AAV which mediates the expression of CaM-
peptide. Before proceeding to an HD animal model, we first tested
the effects of AAV-mediated expression of CaM-peptide in a neu-
ronal HD cell model as neurons are affected in HD and the effects
of CaM-peptide have only been tested in kidney cells. We created
neuroblastoma SH-SY5Y cells which stably express N-terminal
mutant huntingtin and endogenously express TG 2 (SHSY5Y-htt-
N63-148-Q cells; Figure 2A) and examined the effect of AAV-
mediated expression of CaM-peptide on TG-activity and mutant
huntingtin-associated neurotoxicity. Furthermore, we induced dif-
ferentiation of SHSY5Y cells prior to testing the effects of the CaM
peptide to increase the levels of TG expressed in the cells and to
acquire a neuronal phenotype, both effects producing a model
more closely resembling cells that degenerate in HD.
AAV-mediated expression of CaM-peptide was sufficient to
result in effects in SHSY5Y-htt-N63-148-Q cells similar to effects
previously seen in HEK-293 cells. TG-catalyzed modifications of
mutant huntingtin and cytotoxicity were attenuated in SHSY5Y-
htt-N63-148Q cells expressing CaM-peptide compared with
SHSY5Y-htt-N63-148Q cells expressing scram-CaM-peptide or
GFP. These findings make it plausible that AAV-mediated expres-
sion of CaM-peptide could potentially have beneficial effects in an
HD transgenic mouse model.
CaM-peptide was able to attenuate TG-catalyzed modifications
to mutant huntingtin, but it was unclear whether this effect was
specific to TG-catalyzed modifications of mutant huntingtin or if
it was a non-specific effect on TG-catalyzed modifications of all
TG substrates. We used two different approaches to measure total
TG activity, an ex vivo approach in which total TG activity is
measured in lysed cells, and an in situ approach in which an
exogenous substrate is added to the media, taken up by cells and
then modified by TG in situ. Using both the ex vivo and the in
situ approach, TG activity was not significantly affected by
expression of CaM-peptide in either SHSY5Y cells not express-
ing mutant huntingtin (non-htt-SHSY5Y) or in SHSY5Y-htt-N63-
148Q cells. TG activity was significantly increased in SHSY5Y-
htt-N63-148Q cells expressing scram-CaM-peptide or GFP
compared with non-htt-SHSY5Y cells as measured with the in
situ assay. This is similar to the disease state in which there is
elevated TG activity in the brains of HD patients compared with
control subjects (23, 25). However, TG activity in SHSY5Y-htt-
N63-148Q cells expressing CaM-peptide was not significantly
different from non-htt-SHSY5Y cells or from SHSY5Yhtt-N63-
148Q cells expressing scram-CaM-peptide or GFP. The results
suggest that CaM-peptide does not affect TG activity in cells
without mutant huntingtin expression, further indicating that the
effects of CaM-peptide are restricted to the site of interaction
between TG and mutant huntingtin and therefore does not signifi-
cantly affect total TG activity.
Figure 7. The level of CaM-bound huntingtin-exon 1 with an expanded
polyglutamine repeat (htt-exon1-44Q) in the absence and presence of
varying concentrations of CaM-peptide. The amount of CaM-bound htt-
exon1-44Q was significantly lower when 10 mM of CaM-peptide was
present than when no CaM peptide was present (control). Furthermore,
lower concentrations of CaM peptide are required to inhibit self-
aggregated htt-exon1-44Q. However, 10 mM of CaM-peptide did not
affect the binding of CaM with calcineurin, a known CaM-binding
protein. (A) Representative western blot of protein immunoprecipitated
using CaM-agarose. Blot was probed for N-terminal mutant huntingtin.
(C) Representative western blot of protein immunoprecipitated using
CaM-agarose. Blot was probed for calcineurin. (B and D) Quantification
of immunoblots depicted graphically. Data shown are the mean
IOD  standard error of the mean (n = 3). CaM-bound htt-exon1-44Q
data: one-way analysis of variance (F(5,17) = 3.931, P < 0.024) and
Newman–Keuls comparison, * indicates P < 0.05 compared with 10 mM
(CaM-peptide). CaM-bound calcineurin data: two-tailed t-test
(P = 0.8575). Abbreviations: CaM = calmodulin; htt-exon1-148Q =
recombinant exon 1 of huntingtin with 44 glutamines.
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Based on the total TG activity assays, it appeared as though
CaM-peptide specifically alters TG activity associated with mutant
huntingtin but not total TG activity. However, it was unclear
whether CaM-peptide also alters the activity of other CaM-
dependent enzymes. This was important to investigate as not all
CaM-dependent enzymes may have increased activity in HD like
TG, or may not even be altered or involved in HD. TG protein levels
and activity are elevated in human HD brains (24, 25) and there is
increased TG activity as well as immunoreactivity in R6/2 HD
transgenic mouse brains (11). In contrast to TG, CaM kinase II
protein levels are decreased in R6/2 HD transgenic mouse brains
(10), suggesting that there may be a subsequent decrease in CaM
kinase II activity. However, we found that in SHSY5Y cells trans-
fected with mutant huntingtin, there were no significant differences
in CaM kinase II activity compared with control cells transfected
with vector. This suggests that CaM kinase II activity may not be
altered in HD as TG activity is. It is also important to determine
whether expression of CaM-peptide would alter CaM kinase II
activity. We found that expression of CaM-peptide did not signifi-
cantly alter CaM kinase II activity in the HD-model cells or in
control cells compared with cells not expressing CaM-peptide,
suggesting that CaM-peptide does not alter the activity of other
CaM-dependent enzymes. Collectively, these data suggest that
CaM-peptide may specifically affect the CaM-mutant huntingtin
interaction, thereby primarily altering TG-catalyzed modifications
of mutant huntingtin.
Figure 8. The level of CaM-bound huntingtin-exon 1 with an expanded
polyglutamine repeat (htt-exon1-44Q) in the absence and presence of
varying concentrations of CaM-peptide and/or W-5. A. The presence of
W-5 did not alter the amount of CaM-bound htt-exon1-44Q. The amount
of CaM-bound htt-exon1-44Q was significantly lower when 10 mM of
CaM-peptide was present than when W-5 or no CaM peptide was
present (control). However, the amount of CaM-bound htt-exon1-44Q
was significantly increased when 664 mM W-5 is present along with
10 mM of CaM-peptide. (A) Representative western blot of protein
immunoprecipitated using CaM-agarose. Blot was probed for N-terminal
mutant huntingtin. B. Quantification of immunoblot depicted graphically.
Data shown are the mean  SEM (n = 3). Two-way ANOVA
[Factor: W-5 (F(3,23) = 7.712, P = 0.0021)]; Factor: CaM-peptide (F(1,23) =
157.734, P < 0.0001); W-5 ¥ CaM-peptide (F(3,23) = 1.544, P = 0.2417)
and Newman-Keuls comparison. ** indicates P < 0.01 compared with
10 mM (CaM-peptide). * indicates P < 0.05 compared with 10 mM
(CaM-peptide). ∧ indicates P < 0.01 compared with 66 mM W-5 +
10 mM (CaM-peptide). ++ indicates P < 0.01 compared with 210 mM +
W-5 10 mM (CaM-peptide). + indicates P < 0.05 compared with
210 mM W-5 + 10 mM (CaM-peptide). ## indicates P < 0.01 compared
with 664 mM W-5 + 10 mM (CaM-peptide). # indicates P < 0.05 com-
pared with 664 mM W-5 + 10 mM (CaM-peptide). Abbreviations:
CaM = calmodulin; htt-exon1-44Q = recombinant exon 1 of huntingtin
with 44 glutamines.
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As all of the previously observed effects of CaM-peptide have
been in HD cell models, we used a cell-free in vitro assay to deter-
mine if there is a direct interaction between mutant huntingtin and
CaM, and whether the CaM-peptide could interrupt the interaction.
When purified recombinant huntingtin exon 1 with an expanded
polyglutamine repeat was incubated with CaM-agarose, we were
able to detect a direct interaction between the two proteins. This
result differs from previous work in which an 125I-CaM overlay
experiment was performed with purified rat huntingtin and 125I-
CaM failed to bind huntingtin, suggesting that huntingtin and CaM
did not bind directly (3). Differences in experimental design could
account for the different outcomes. In comparison to the previous
study that used full-length, wild-type huntingtin purified from
rat brain, we used recombinant huntingtin consisting of exon 1
and having an expanded polyglutamine repeat containing 44
glutamines (htt-exon1-44Q). One possibility is that the poly-
glutamine expansion in the mutant form of huntingtin increases its
affinity for CaM, allowing huntingtin to interact with CaM directly.
Another possibility is that the exon 1 fragment of huntingtin has an
altered conformation in which the CaM-binding region may be
exposed, where otherwise it is masked in the full-length huntingtin
structure. Furthermore, the wild-type huntingtin protein sample
was resolved by SDS-PAGE and transferred to a membrane which
was incubated with 125I-CaM. It has been shown that some proteins
are unable to renature upon transfer to a membrane (4). Possibly,
the CaM-binding domains of the 350 kDa huntingtin protein failed
to renature on the membrane. We performed our CaM-binding
experiments by incubating the htt-exon1-44Q protein sample with
CaM-agarose, allowing huntingtin to be in a native state. Lastly, the
relative protein concentrations used in the previous experiments
may be problematic. In the previous 125I-CaM overlay experiments,
125I-CaM failed to bind purified rat huntingtin but bound the posi-
tive control, calcineurin. However, only 150 ng (0.43 pmoles) of
purified rat huntingtin was used but 500 ng (6.25 pmoles) of cal-
cineurin was used. Calcineurin is one of the highest affinity CaM-
binding proteins examined to date (having a Kd = 28 pmols for
binding of calcineurin to calcium-saturated CaM) (37). Therefore,
it is likely that huntingtin has a lower affinity for CaM compared
with calcineurin. In the previous study, an interaction between hun-
tingtin and CaM may not have been detected simply because of the
problem that there was not enough huntingtin present. In this study,
8.4 mg (560 pmoles) of recombinant htt-exon1-44Q was incubated
with 45 mg (2.7 nmoles) of CaM which is within the range of
amounts used in other protein-CaM-agarose binding studies:
~37.5 mg (1.5 nmoles) of RGS4 with 26 mg (1.5 nmoles) of CaM
(35); 10 mg (310 pmoles) of regucalcin with 90 mg (5.4 nmoles) of
CaM (32); and 10 mg (500 pmoles) of FK506-binding protein
(AtFKBP42) with CaM (22).
After a direct interaction between htt-exon1-44Q and CaM was
established, we found that 10 mM of CaM-peptide was able to
significantly inhibit the interaction between CaM and htt-exon1-
44Q. The peptide concentration of 10 mM that was needed to
inhibit CaM-mutant huntingtin binding is similar to concentrations
required for other synthetic peptides to inhibit protein–protein
interactions (14). The presence of W-5 did not affect the interaction
between htt-exon1-44Q and CaM. These data suggest that in our
previous study, the decreased TG-catalyzed modifications of hun-
tingtin we observed when inhibiting CaM with W-5 (49) was most
likely caused by inhibition of CaM activity and not caused by
inhibiting the binding of CaM to mutant huntingtin. Furthermore,
the presence of 664 mM W-5, but not lower concentrations (66 mM,
210 mM), attenuated the effect of 10 mM CaM-peptide, i.e. to
inhibit CaM-mutant huntingtin binding. However, the amount of
CaM-bound htt-exon1-44Q was still significantly less than when
CaM-peptide was not present. This suggests that CaM-peptide may
bind CaM at the site of interaction of W-5, but that CaM-peptide
has a higher affinity necessitating a high concentration of W-5 (half
a log more than the IC50 of 210 mM) (20, 40) to inhibit binding of
CaM-peptide to CaM. Lastly, the lack of an effect of CaM-peptide
on the interaction of CaM and calcineurin suggests that CaM-
peptide may act directly on CaM and mutant huntingtin and not on
other proteins that interact with CaM. As calcineurin has such a
high affinity for CaM, the effect of CaM-peptide on the interactions
of CaM and other CaM-binding proteins should be examined.
However, the expression of the CaM-peptide reduced cytotoxicity
in both the neuronal cell model and in a kidney cell model, which
suggest that the CaM-peptide is not likely to interfere with crucial
interactions of CaM with other proteins.
We previously demonstrated that CaM is associated with the
aggregates of mutant huntingtin protein (49). Other lines of evi-
dence also support a role for CaM in HD. The CaM binding protein,
PEP-19, which inhibits calcium-CaM signaling (38, 39), has been
shown to be decreased in HD brain regions that are vulnerable to
degeneration (45). This decreased the inhibition of CaM, combined
with the close proximity of TG and CaM (caused by the interaction
of mutant huntingtin with both proteins) may contribute to CaM-
mediated over-stimulation of TG. It has been shown that TG activ-
ity is increased in HD brains (23, 25). Increased TG activity can
result in increased modifications and stabilization of aggregated
and monomeric mutant huntingtin as well as oligomers of mutant
huntingtin fragments. The binding of CaM to exon 1 of mutant
huntingtin may result in the inhibition of the normal biochemical
functions of CaM such as activating NOS. It has been shown that in
R6/2 HD transgenic mice, NOS activity is reduced and NOS inhi-
bition accelerates behavioral deficits (9). There are abnormally
high levels of cytosolic calcium in HD transgenic mice (43), and
mitochondria from HD patients display abnormal calcium homeo-
stasis (33). Furthermore, huntingtin with an expanded glutamine
repeat increases inositol 1,4,5-trisphosphate receptor-mediated
calcium release (41–43). These deleterious effects on calcium
homeostasis suggest that returning the functioning of CaM toward
normal would be beneficial. The ability of the CaM peptide to
inhibit the binding of CaM and N-terminal mutant huntingtin could
result in increased functioning of CaM, assuaging the disturbed
calcium homeostasis as previously shown in HEK-293 cells (13).
Our current findings illustrate that the expression of CaM-
peptide in a neuronal HD cell model results in decreased
TG-modifications of mutant huntingtin and decreased cytotoxicity.
Our in vitro findings support the hypothesis that expression of a
small fragment of CaM can regulate the binding of CaM and
mutant huntingtin, and taken together with the cell culture data,
suggest that interrupting this binding provides neuroprotective
effects against the detrimental consequences associated with
mutant huntingtin expression. Importantly, the CaM-peptide shows
selective effects on TG-mediated modifications to mutant hunting-
tin and do not affect any other CaM-regulated enzymes or TG
activity in general. The AAV-expressed CaM-peptide will next be
tested in an HD transgenic mouse model. Inhibiting the interaction
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of CaM with mutant huntingtin protein is a potential target for
therapeutic intervention in HD.
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